 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- |||| ecnoglutide SC (XW003) / Sciwind Biosci
Trial primary completion date: A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity (clinicaltrials.gov) - Jul 4, 2024
P3, N=664, Active, not recruiting, Sponsor: Hangzhou Sciwind Biosciences Co., Ltd.
Trial primary completion date: Jan 2025 --> Jun 2024
- ecnoglutide SC (XW003) / Sciwind Biosci
A Phase 3 Evaluation of cAMP Signaling Biased GLP-1 Analog Ecnoglutide (XW003) in Adults with Type 2 Diabetes (Poster Hall (West A4-B2); 742) - May 20, 2024 - Abstract #ADA2024ADA_3254;
Trial primary completion date: Jan 2025 --> Jun 2024 Ecnoglutide resulted in robust HbA1c declines of up to 2.43% from baseline after 24 weeks of treatment in adults with T2DM, with up to 35.2% of participants reaching normoglycemia (HbA1c <5.7%) and 43.7% with weight reductions ?5%.
- ecnoglutide SC (XW003) / Sciwind Biosci
Biased GLP-1 Analog Ecnoglutide (XW003) Has Improved Efficacy Relative to Unbiased Peptides (Poster Hall (West A4-B2); 793) - May 20, 2024 - Abstract #ADA2024ADA_2824;
Funding By Sciwind Biosciences Introduction & Objective: Ecnoglutide (XW003) is a cAMP-biased GLP-1 analog being developed for the treatment of type 2 diabetes mellitus (T2DM) and obesity. Bias for the cAMP pathway results in sustained signaling that correlates with increased clinical efficacy compared to unbiased GLP-1 analogs.
- cagrilintide (AM833) / Novo Nordisk, ecnoglutide SC (XW003) / Sciwind Biosci
Synergistic Body Weight Reduction of GLP-1 Analog Ecnoglutide and Amylin Analogs in Preclinical Animal Models (Poster Hall (West A4-B2); 788) - May 20, 2024 - Abstract #ADA2024ADA_2819;
Novel amylin analogs (Cmpd A and Cmpd B) showed similar in vitro activities to cagrilintide. In preclinical animal models, combination of amylin analogs with GLP-1 analog ecnoglutide demonstrated a synergistic effect on body weight reduction.
- | ecnoglutide SC (XW003) / Sciwind Biosci
New P1 trial: Pharmacokinetic Study of XW003 Injection in Subjects with Normal Renal Function and Renal Insufficiency (EUDRACT) - Dec 5, 2023
P1, N=30, Recruiting, Sponsor: Clinical Trial Center of Third Xiangya Hospital of Central South University; Third Xiangya Hospital, Central South University
In preclinical animal models, combination of amylin analogs with GLP-1 analog ecnoglutide demonstrated a synergistic effect on body weight reduction. .
- |||| ecnoglutide SC (XW003) / Sciwind Biosci
Trial completion: Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity (clinicaltrials.gov) - Aug 21, 2023
P2, N=206, Completed, Sponsor: Sciwind Biosciences APAC CO Pty. Ltd.
. Recruiting --> Completed
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk, ecnoglutide SC (XW003) / Sciwind Biosci
Journal: Discovery of ecnoglutide - a novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog. (Pubmed Central) - Aug 7, 2023
P1
Ecnoglutide showed a favorable potency, pharmacokinetic, and tolerability profile, as well as a simplified manufacturing process. These results support the continued development of ecnoglutide for the treatment of type 2 diabetes and obesity.
- ||||| ecnoglutide SC (XW003) / Sciwind Biosci
Enrollment closed: A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity (clinicaltrials.gov) - Jul 17, 2023
P3, N=664, Active, not recruiting, Sponsor: Hangzhou Sciwind Biosciences Co., Ltd.
These results support the continued development of ecnoglutide for the treatment of type 2 diabetes and obesity. Not yet recruiting --> Active, not recruiting
- ||||| ecnoglutide SC (XW003) / Sciwind Biosci
Enrollment closed: A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM (clinicaltrials.gov) - Jul 17, 2023
P3, N=623, Active, not recruiting, Sponsor: Hangzhou Sciwind Biosciences Co., Ltd.
Not yet recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| ecnoglutide SC (XW003) / Sciwind Biosci
Enrollment closed: A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients (clinicaltrials.gov) - Jul 17, 2023
P3, N=211, Active, not recruiting, Sponsor: Hangzhou Sciwind Biosciences Co., Ltd.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ecnoglutide SC (XW003) / Sciwind Biosci, Saxenda (liraglutide 3 mg) / Novo Nordisk
An Open-Label, Active-Controlled Phase 2 Evaluation of Novel GLP-1 Analog Ecnoglutide in Adults with Obesity (Poster Halls B-C; [Board No. 79]) - Apr 29, 2023 - Abstract #ADA2023ADA_3109;
Recruiting --> Active, not recruiting Ecnoglutide (XW003) is a novel, long-acting GLP-1 analog being developed for the treatment of type 2 diabetes mellitus (T2DM) and obesity...Participants were randomized to receive target doses of ecnoglutide at 1.2, 1.8, or 2.4 mg as once weekly SC injections or liraglutide (Saxenda
- |||||||||| ecnoglutide SC (XW003) / Sciwind Biosci
New P3 trial: A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity (clinicaltrials.gov) - Apr 14, 2023
P3, N=660, Not yet recruiting, Sponsor: Hangzhou Sciwind Biosciences Co., Ltd.
- ecnoglutide SC (XW003) / Sciwind Biosci
A Phase 1c Evaluation of a Novel GLP-1 Analog Ecnoglutide (XW003) for Weight Loss in Adults with Overweight and Obesity (Poster Halls B-C; [Board No. 756]) - Apr 10, 2023 - Abstract #ADA2023ADA_1343;
The most frequent AEs were gastrointestinal, including diarrhea and vomiting. No drug-related SAE or drug-related AEs ?Grade 3 were reported.
- ecnoglutide SC (XW003) / Sciwind Biosci
A Phase 2 Evaluation of a Novel GLP-1 Analog Ecnoglutide (XW003) for Glycemic Control in Adults with Type 2 Diabetes (Poster Halls B-C; [Board No. 755]) - Apr 10, 2023 - Abstract #ADA2023ADA_1342;
The proportion of participants reporting any AE ranged from 72.2 to 78.4% for ecnoglutide and 58.3 % for placebo. The most frequently reported AEs were gastrointestinal, including diarrhea and nausea.
- |||||| ecnoglutide SC (XW003) / Sciwind Biosci
Enrollment open: A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM (clinicaltrials.gov) - Mar 21, 2023
P3, N=600, Recruiting, Sponsor: Hangzhou Sciwind Biosciences Co., Ltd.
The most frequently reported AEs were gastrointestinal, including diarrhea and nausea. Not yet recruiting --> Recruiting
- |||||| ecnoglutide SC (XW003) / Sciwind Biosci
Enrollment open: A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients (clinicaltrials.gov) - Feb 8, 2023
P3, N=210, Recruiting, Sponsor: Hangzhou Sciwind Biosciences Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| ecnoglutide SC (XW003) / Sciwind Biosci
New P3 trial: A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM (clinicaltrials.gov) - Jan 11, 2023
P3, N=600, Not yet recruiting, Sponsor: Hangzhou Sciwind Biosciences Co., Ltd.
- |||||||||| ecnoglutide SC (XW003) / Sciwind Biosci
New P3 trial: A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients (clinicaltrials.gov) - Jan 11, 2023
P3, N=210, Not yet recruiting, Sponsor: Hangzhou Sciwind Biosciences Co., Ltd.
- XW003 / Sciwind Biosci
Synergistic activity of GLP-1 peptide analog XW003 and the long-lasting GIP receptor agonist XW017 in a diet induced obese mouse model (Poster Area) - Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_1690;
Not yet recruiting --> Recruiting In conclusion, combinatory treatment of GLP-1 and GIP receptor agonists showed a synergistic effect on promoting weight loss in a mouse model of obesity.
- ||| ecnoglutide SC (XW003) / Sciwind Biosci
Enrollment open: Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity (clinicaltrials.gov) - Dec 23, 2021
P2, N=200, Recruiting, Sponsor: Sciwind Biosciences APAC CO Pty. Ltd.
In conclusion, combinatory treatment of GLP-1 and GIP receptor agonists showed a synergistic effect on promoting weight loss in a mouse model of obesity. Not yet recruiting --> Recruiting
- |||| ecnoglutide SC (XW003) / Sciwind Biosci
New P2 trial: Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity (clinicaltrials.gov) - Nov 7, 2021
P2, N=200, Not yet recruiting, Sponsor: Sciwind Biosciences APAC CO Pty. Ltd.
- ||| ecnoglutide SC (XW003) / Sciwind Biosci
Trial completion, Trial completion date: To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult Participants (clinicaltrials.gov) - Oct 27, 2021
P1, N=64, Completed, Sponsor: Sciwind Biosciences APAC CO Pty. Ltd.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial completion date: Dec 2021 --> Sep 2021
- || ecnoglutide SC (XW003) / Sciwind Biosci
Enrollment closed, Trial completion date, Trial primary completion date: To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult Participants (clinicaltrials.gov) - Sep 30, 2021
P1, N=64, Active, not recruiting, Sponsor: Sciwind Biosciences APAC CO Pty. Ltd.
Active, not recruiting --> Completed | Trial completion date: Dec 2021 --> Sep 2021 Recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Oct 2021
- || ecnoglutide SC (XW003) / Sciwind Biosci
New P1 trial: To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult Participants (clinicaltrials.gov) - May 14, 2020
P1, N=50, Recruiting, Sponsor: Sciwind Biosciences APAC CO Pty. Ltd.